Tarceva

Type: Product
Name: Tarceva
First reported 1 hour ago - Updated 1 hour ago - 1 reports

TKIs Combined With Other Drugs May Prove More Effective in NSCLC

James CH Yang, MD, PhDTyrosine kinase inhibitors (TKIs) are effective as single agents in EGFR-positive non-small cell lung cancer (NSCLC), but investigators continue to ask questions about how to improve the results of these agents.Can TKIs be combined ... [Published OncLive - 1 hour ago]
First reported 16 hours ago - Updated 16 hours ago - 1 reports

Showcase, August 2014

New approvalRecombinant C1-esterase inhibitor (Ruconest—Pharming Group NV, Salix Pharmaceuticals) treats acute attacks in adult and adolescent patients with hereditary angioedema (HAE).HAE is caused by having insufficient amounts of a plasma protein called ... [Published Pharmacist.com - 16 hours ago]
First reported 23 hours ago - Updated 23 hours ago - 1 reports

Afatinib plus cetuximab shows promise for EGFR -mutated lung cancer

Afatinib plus cetuximab demonstrated clinical activity and a manageable safety profile in patients with EGFR -mutant lung cancers with acquired resistance to gefitinib or erlotinib, both with and without T790M mutations, according to findings in an early-phase ... [Published Orthopedics Today - 23 hours ago]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

Ambitious Lung-MAP Trial Launched With Five Novel Drugs

Anita T. ShafferVassiliki Papadimitrakopoulou, MDFive novel agents for the treatment of patients with advanced squamous cell carcinoma of the lung will be evaluated in the recently launched Lung-MAP trial, an innovative biomarker-driven study that aims ... [Published OncLive - Jul 31 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

AstraZeneca's AZD-9291 and Clovis Oncology's CO-1686 look poised to advance the treatment paradigm for EGFR-positive non-small-cell

(live-PR.com) - Propelled via momentum from new data presented at the ASCO annual meeting, AstraZeneca´s AZD-9291 and Clovis Oncology´s CO-1686 look poised to advance the treatment paradigm for EGFR-positive non-small-cell lung cancer (NCSLC) patients ... [Published Live-PR.com - Jul 31 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Treatment Combo Benefits Lung Cancer Patients

A combination of the EGFR-targeted anticancer therapeutics afatinib ( Gilotrif ) and cetuximab (Erbitux) yielded clinical responses in 29% of patients who had lung cancer harboring epidermal growth factor receptor (EGFR) mutations that had stopped responding ... [Published BioPortfolio - Jul 30 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Treatment Combo for EGFR Inhibitor-Resistant Lung Cancer

The combination of two epidermal growth factor receptor (EGFR) targeted therapies showed clinical responses among advanced lung cancer patients who had previously stopped responding to monotherapy treatment with other EGFR inhibitors. Twenty-nine percent ... [Published Cancernetwork.com - Jul 30 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

More pharma firms trying to settle patent rows via talks

Cipla and F. Hoffmann-La Roche are in talks to settle the Tarceva patent infringement case that dates back to 2008. Photo: S. Kumar/MintMumbai: Indian generics or copycat drug makers and multinational pharma companies are increasingly resorting to mediation ... [Published Livemint.com - Jul 29 2014]
First reported Jul 28 2014 - Updated Jul 29 2014 - 1 reports

AZ signs two companion diagnostic deals

AstraZeneca has signed a brace of deals for new diagnostics that will help identify patients suitable for treatment with its lung cancer therapies Iressa and AZD9291.New cancer drugs are increasingly targeted to patients with a , so it is important to ... [Published PMLive - Jul 28 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Drugs to Avoid in Patients on Tyrosine Kinase Inhibitors

With the rapid and widespread uptake of tyrosine kinase inhibitors (TKIs) in oncology over the past several years, serious drug–drug interactions are an "increasing risk," according a new report.To guarantee the safe use of TKIs, "a drugs review for each ... [Published Diabetes Care - Jul 25 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 2 reports

CIP2A pathway involved in erlotinib response

Researchers have identified a novel mechanism, involving the cancerous inhibitor of protein phosphatase 2A pathway, which mediates the anti-tumour effects of erlotinib in non-small-cell lung cancer cells without epidermal growth factor receptor mutat ... [Published BioPortfolio - Jul 16 2014]
First reported Jul 03 2014 - Updated Jul 04 2014 - 2 reports

Forum Post: RE: Tarceva Help,,,,

A group for anyone affected by lung cancer to get together, ask questions, share experiences and support each other.Tarceva Help,,,,Posted by jeneil on3 Jul 2014 11:32 PMHi, my husband has NSCLung and lymph node involvement. He started tarceva 16days ... [Published Macmillan Cancer Support - Jul 04 2014]

Quotes

The following quote was obtained by the news editors from the background information supplied by the inventors: "Adverse effects, occurred in cancer patients receiving radiation therapy and chemotherapy, are well known. The toxicity of anticancer therapy has always been a major concern of patients because such therapy causes serious adverse effects. For patients who cannot complete the intended course of treatment, the therapy not only fails to achieve the desired and predicted outcome but the medical resources are also wasted. Because of its relatively non-selective action on both normal and cancer cells, radiation therapy and chemotherapy not only eliminate cancer cells but may also kill normal cells. Common adverse effects for patients receiving these treatments include oral ulcers, loss of appetite, diarrhea, hair loss, and a decrease of white blood cells and platelets, which can lead to other fatal complications. Adverse effects often limit the therapeutic dosages administered, and hence the therapeutic efficacy; part of the adverse effects can be reduced by changing drug delivery, such as dividing the doses or increasing the administration duration or local administration. Examples of the latter include intraperitoneal or intra-arterial chemotherapy, which limits the systemic adverse effects by confining high concentrations of drugs to the lesion sites; or administering antagonists (or antidotes) after the drugs have exerted their therapeutic effects, which may reduce the toxic effects of anticancer drugs on normal cells. However, the above approaches are not selective, and there is only a marginal decrease in the toxicity to normal cells; moreover, the therapeutic efficacy on cancer cells is also compromised. The alternative approach is to treat the adverse effects immediately after drug administration to minimize the harmful effects, such as administering white blood cellcell growth factors and potent antiemetic agents; however, this approach only partially reduces the existing adverse effects, and lacking preventive effects. It is impossible to have a drug exhibiting only therapeutic effect and no adverse effects. Furthermore, once the tumor is formed, relentless replication and growth of cancer cells will metastasize to distant organs via blood and lymphatic vessels, which may ultimately produce drug resistance cancer cells leading to treatment failure. Anticancer and radiation therapy are no longer effective in controlling tumor growth and spread. Accordingly, the focal point to consider in radiotherapy and chemotherapy is to attack cancer cells while concomitantly protect normal cells to reach the goal of radiotherapy and chemotherapy. Since the actionaction mechanism of chemotherapy and radiation therapy is partially due to free radical damage, a rational selective utilization of substances possessing both antioxidant and free radical property can reduce the damage to normal cells under such treatment."
"The use of circulating tumour DNA (ctDNA) testing will allow doctors to target the individual needs of each patient quickly and accurately" he said

More Content

All (156) | News (127) | Reports (0) | Blogs (27) | Audio/Video (0) | Fact Sheets (2) | Press Releases (0)
sort by: Date | Relevance
TKIs Combined With Other Drugs May Prove More E... [Published OncLive - 1 hour ago]
Astellas Pharma's (ALPMF) Q2 2014 Results - Ear... [Published Seeking Alpha - 6 hours ago]
Showcase, August 2014 [Published Pharmacist.com - 16 hours ago]
Exelixis' (EXEL) CEO Michael Morrissey on Q2 20... [Published Seeking Alpha - 20 hours ago]
Afatinib plus cetuximab shows promise for EGFR ... [Published Orthopedics Today - 23 hours ago]
Ambitious Lung-MAP Trial Launched With Five Nov... [Published OncLive - Jul 31 2014]
Lung Congress to Offer Thorough Review of Lates... [Published OncLive - Jul 31 2014]
AstraZeneca's AZD-9291 and Clovis Oncology's CO... [Published Live-PR.com - Jul 31 2014]
Patent Issued for Drug Carrier with Chelating C... [Published HispanicBusiness.com - Jul 31 2014]
Treatment Combo Benefits Lung Cancer Patients [Published BioPortfolio - Jul 30 2014]
Treatment Combo for EGFR Inhibitor-Resistant Lu... [Published Cancernetwork.com - Jul 30 2014]
More pharma firms trying to settle patent rows ... [Published Livemint.com - Jul 29 2014]
Promising Findings for AfatinibâCetuximab Combo... [Published OncLive - Jul 29 2014]
New treatment combination benefited patients wi... [Published Ecancer Medicalscience - Jul 29 2014]
Advanced NSCLC: Modest Survival Gain with Use o... [Published Oncology Times - Jul 29 2014]
AZ signs two companion diagnostic deals [Published PMLive - Jul 28 2014]
Drugs to Avoid in Patients on Tyrosine Kinase I... [Published Diabetes Care - Jul 25 2014]
Roche Holding AG's (RHHBY) CEO Daniel O'Day on ... [Published Seeking Alpha - Jul 25 2014]
Lung-MAP Trial Debuts—Other Personalized Studie... [Published The ASCO Post - Jul 24 2014]
Bolt-ons rather than big deals for Roche CEO [Published Pharma Times - Jul 24 2014]
"Process for Preparation of Erlotinib and Its P... [Published 4 Traders - Jul 24 2014]
CRIPTO1 role in TKI resistance elucidated [Published News-Medical.Net - Jul 23 2014]
Co-targeting strategies suggested for EGFR-TKI ... [Published News-Medical.Net - Jul 23 2014]
ZIOPHARM Oncology : Researchers Submit Patent A... [Published 4 Traders - Jul 23 2014]
Durable Response to Crizotinib in a MET -Amplif... [Published Sexual Development - Jul 23 2014]
Cabozantinib Reduces Tumor Growth After Erlotin... [Published OncLive - Jul 22 2014]
Increased overall survival for advanced stage n... [Published EurekAlert! - Jul 21 2014]
Blog Post: Staying Alive [Published Macmillan Cancer Support - Jul 18 2014]
Molecularly Targeted Therapy for Lung Cancer [Published The ASCO Post - Jul 17 2014]
Loxo Oncology Expands Leadership Team With Key ... [Published Town Hall - Jul 17 2014]
1 2 3 4 5 6
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Advancing medicine, layer by layer [Published MIT News feed - Jul 01 2014]
Personalized cancer treatments and better bone implants could grow from techniques demonstrated by graduate students Stephen W. Morton and Nisarg J. Shah, who are both working in chemical engineering professor Paula Hammond's lab at MIT. Morton's work ...
Tarceva Forecast [Published PR Newswire: Entertainment & Media - Jun 19 2014]
NEW YORK, June 19, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:Tarceva Forecasthttp://www.reportlinker.com/p02162048/Tarceva-Forecast.htmlThe BCC Research Tarceva Forecast is a quantitative ...
Faculty highlight: Paula Hammond [Published MIT News feed - Jun 18 2014]
As a chemical engineer, Paula Hammond began her career getting tiny polymers to transform when heated or stretched — by changing color, for example. But her passion turned to using those techniques to promote healing. That led her to engineer better ...
FibroGen Announces Results of Phase 2 Study of ... [Published Business Wire Health News - May 31 2014]
CHICAGO--(BUSINESS WIRE)--FibroGen, Inc. (FibroGen) today announced results from a Phase 2 open-label study of FG-3019, an investigational anti-fibrotic antibody, in combination with gemcitabine and erlotinib for the treatment of patients with locally ...
Genprex Begins Phase II Clinical Trial for Lung... [Published PR Newswire: Health - May 20 2014]
AUSTIN, Texas, May 20, 2014 /PRNewswire/ -- Genprex, Inc. announced today that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex® in combination with erlotinib (Tarceva®) for late-stage lung cancer patients. ...
1 2 3 4 5 6
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.